S ingle-level transforaminal lumbar interbody fusion (TLIF) is a commonly performed procedure used to treat degenerative conditions of the lumbar spine. During this procedure the intervertebral disc is removed and a spacer is inserted between the 2 vertebral bodies to achieve interbody fusion. Failure of fusion is a challenging problem that can lead to ongoing low-back pain and dependence on pain medication and adversely impact the aBBreViatiONS ICBG = iliac crest bone graft; ODI = Oswestry Disability Index; PEEK = polyetheretherketone; rhBMP-2 = recombinant human bone morphogenetic protein-2; TLIF = transforaminal lumbar interbody fusion; VAS = visual analog scale. SuBmitted December 4, 2012. accepted November 24, 2013. iNclude wheN citiNg Published online January 23, 2015; DOI: 10.3171/2013.11.SPINE121106. diSclOSure This study was funded by Biosurface Engineering Technology (BioSET). Dr. Anderson reports that he is the medical monitor for the study described in this article and has received BioSET stock options for his work as medical monitor. Dr. Jarzem reports receiving support from BioSET for the study described. OBJect Failure of fusion after a transforaminal lumbar interbody fusion (TLIF) procedure is a challenging problem that can lead to ongoing low-back pain, dependence on pain medication, and inability to return to work. B2A is a synthetic peptide that has proven efficacy in achieving fusion in animal models and may have a better safety profile than bone morphogenetic protein. The authors undertook this study to evaluate the safety and efficacy of B2A peptide-enhanced ceramic granules (Prefix) in comparison with autogenous iliac crest bone graft (ICBG, control) in patients undergoing single-level TLIF. methOdS Twenty-four patients with single-level degenerative disorders of the lumbar spine at L2-S1 requiring TLIF were enrolled between 2009 and 2010. They were randomly assigned to 3 groups: a control group (treated with ICBG, n = 9), a Prefix 150 group (treated with Prefix 150 mg/cm 3 granules, n = 8), and a Prefix 750 group (treated with Prefix 750 mg/cm 3 granules, n = 7). Outcome measures included the Oswestry Disability Index (ODI), visual analog pain scale, and radiographic fusion as assessed by CT and dynamic flexion/extension lumbar plain radiographs. reSultS At 12 months after surgery, the radiographic fusion rate was 100% in the Prefix 750 group, 78% in the control group, and 50% in the Prefix 150 group, although the difference was not statistically significant (p = 0.08). At 6 weeks the mean ODI score was 41.0 for the control group, 27.7 for the Prefix 750 group, and 32.2 for the Prefix 150 group, whereas at 12 months the mean ODI was 24.4 for control, 31.1 for Prefix 750, and 29.7 for Prefix 150 groups. Complications were evenly distributed among the groups. cONcluSiONS Prefix appears to provide a safe alternative to autogenous ICBG. Prefix 750 appears to show superior radiographic fusion when compared with autograft at 12 months after TLIF, although no statistically significant difference was demonstrated in this small study. Prefix and control groups both appeared to demonstrate comparable improvements to ODI at 12 months.
ability to return to work. The historic gold standard for graft, iliac crest bone graft (ICBG), used to fill the intervertebral disc space during spinal fusions due to its osteoinductive and osteoconductive properties as well as low immunogenicity, 3, 4, 14, [19] [20] [21] 26 ,27 is associated with increased morbidity related to the donor site from which the graft is harvested. 5, 7, [12] [13] [14] 19, 20, 22, 23, 25, 27, 30, 31 These complications include nerve injury, hematoma, infection, fracture, and hernias. 5, 13, 14, 20, 22, 23, 25, 30, 31 Minimally invasive techniques 19 for ICBG harvesting have been described that result in less morbidity than the regular open technique but limit the amount of cancellous bone graft that can be harvested. Even if one chose to overlook the morbidity associated with ICBG, there are instances when it is not possible to harvest bone from the iliac crest 3, 21, 27 due to previous harvesting or pelvic dysmorphism. 21 Therefore, other biological and synthetic sources of graft have been identified. [1] [2] [3] [4] [12] [13] [14] [15] [16] [19] [20] [21] 26, 28 Local bone autograft from the site of surgery is commonly used in posterior lumbar interbody fusions 17 and has been shown to be comparable to ICBG in achieving fusion. Several other sites for autogenous bone graft harvesting from extremities of the patients, 20 including intramedullary reaming debris collected from the patient's femur, 7, 21 have been used in spine surgery but have not been routinely adopted due to potential complications. Nevertheless, autograft is still associated with a significant pseudarthrosis rate that may be as high as 26% in some series. 14 In an effort to avoid the problems associated with autograft and the possibility of disease transmission associated with allograft, synthetic alternatives such as recombinant human bone morphogenetic protein-2 (rhBMP-2) 9, 10, 29, 31 have been developed. Unfortunately, significant complications, including some life-threatening events, have been reported with the use of rhBMP-2. 2, 3, 10, 14, 24, 29 The literature regarding complications with rhBMP-2 usage is quite variable, with some authors suggesting complication rates between 10% and 50% for posterior lumbar interbody fusion. Others, such as Glassman et al., 10 have reported a low complication rate of 0.6% with rhBMP-2 when used for posterolateral spine fusion. This degree of variability suggests the need to evaluate the safety profile of rhBMP-2 in a site-and procedure-specific manner.
29 Reported complications include radiculitis, ectopic bone formation, osteolysis, greater apparent risk of malignancy, neurological compromise from bony overgrowth, and inferior overall outcomes. 3 Concerns regarding the safety of rhBMP-2 have led to interest in a number of alternatives to rhBMP-2, such as bioactive glass, 12 recombinant platelet-derived growth factor, 6 ,27 and platelet-rich plasma added to ICBG. 28 However, their efficacy in achieving lumbar interbody fusion in humans has not been proven.
B2A is a synthetic peptide that amplifies the biological response to native BMP-2 through interaction with BMP receptors, leading to increased osteoblast differentiation. 18 As B2A requires native endogenous BMP-2 for activity, it will not form bone in areas where BMP-2 is not already present and may therefore have a better safety profile compared with exogenous rhBMPs. Potential advantages over rhBMP-2 include a reduced risk of malignancy, ectopic bone formation, and neurological compromise from bony overgrowth. However, these are theoretical advantages that have not been confirmed. B2A has both osteoinductive and osteoconductive properties and has proven superiority to autograft in achieving spinal interbody fusion in animal models, 4, 26 with no reports of heterotopic ossification. It has also been shown to provide accelerated bone repair in rabbit long bone defects 18 and has been shown to be comparable to autograft in a pilot study assessing ankle and hindfoot arthrodesis in humans. 11 Encouraged by these results, we designed the current study to test the safety and effectiveness of B2A-coated ceramic granules (Prefix) in humans. This is the first multicenter, prospective, randomized, partially blinded control trial evaluating the safety and the potential effectiveness of Prefix in comparison with autogenous ICBG (control) in achieving fusion in patients undergoing singlelevel TLIF for degenerate disorders of the lumbar spine. We report on the Canadian patients from a Phase I clinical trial, and hence the focus of this study is to establish the safety and appropriate dosage of Prefix required to achieve fusion. We hypothesize that Prefix would achieve a fusion rate equivalent or superior to that of ICBG and would be safe to use.
methods
This study was approved by the institutional review boards of all the centers involved and conducted under Health Canada investigational testing authorization. It was registered with the ClinicalTrials.gov database (http:// clinicaltrials.gov), under the following registration numbers: NCT00798902 and NCT00798239. Twenty-four patients with single-level degenerative disorders of the lumbar spine (degenerative disc disease, spinal stenosis, spondylolisthesis) at L2-S1 requiring TLIF were enrolled between 2009 and 2010 at 5 Canadian centers (Fig. 1) . Patients were recruited into the study and provided informed consent prior to randomization and assignment to the 3 treatment groups: control (ICBG), Prefix 150 (ceramic granules coated with B2A at 150 mg/cm 3 granules), and Prefix 750 (ceramic granules coated with B2A at 750 mg/ cm 3 granules). Patients were randomized (Table 1) in sequential chronological order using a block randomization protocol stratified across all of the study sites. The patients who were assigned to one of the two Prefix groups were blinded to dosage (i.e, were not aware of whether they had been assigned to the Prefix 150 or Prefix 750 group), but patients could not be blinded to control versus Prefix group assignment due to the incision necessary for harvesting the graft in patients in the control group. The patients were required to meet all inclusion and exclusion criteria as listed in Table 2 .
Surgical technique and Outcome measures
Prefix was prepared from vials of lyophilized B2A peptide and porous, ceramic granules (80% tri-calciumphosphate/20% hydroxyapatite, Biomatlante). For the Prefix 150 group, ceramic granules were coated with B2A at 150 mg/cm 3 of granules. For Prefix 750, ceramic granules were coated with B2A at 750 mg/cm 3 of granules. Five cu-bic centimeters of coated granules were then mixed in a 1:1 ratio with locally derived autologous bone (from the lamina and facet joint area) giving a total of 10 cm 3 of graft material to be used. For patients randomized to the control group, bone was harvested from the posterior iliac crest and was not mixed with local autograft. The appropriate graft material was then packed in and around the polyetheretherketone (PEEK) cages. The appropriately filled PEEK TLIF cages were inserted by a typical TLIF approach, which included a unilateral complete facetectomy at the diseased level to gain access to the intervertebral space. Bilateral decompression was performed when required. In all groups, 1 cm 3 of local autograft was packed into the decorticated contralateral facet joint. Posterior instrumentation with standard pedicle screws and rod systems was performed in all cases using the following systems: 1) Medtronic CD Horizon Legacy 5.5-mm titanium spinal set and Capstone PEEK spinal system or 2) Stryker Adaptive Vertebral PEEK Spacer (AVS) and Stryker Xia 5.5-mm titanium implant system. Perioperative data, such as blood loss, length of surgery, length of hospital stay, and complications, were recorded.
Postoperative rehabilitation plans were similar among patients and did not permit systemic treatment with non- scores, visual analog scale (VAS) scores, and fusion outcome as assessed by CT scans (6 and 12 months postoperative) and anteroposterior, lateral, and dynamic lumbar flexion/extension plain radiographs. All radiological data were interpreted by an independent radiologist blinded to group assignment, and a quantitative software program was used to determine motion (Medical Metrics). Fusion was defined as the presence of visible bridging bone on CT scan (Figs. 2 and 3 ), less than 50% radiolucency around the cage, less than 5° of motion, and less than 3 mm of translation on dynamic flexion/extension radiographs. All those criteria needed to be met for fusion to be confirmed. Patients were evaluated at 6 weeks and at 3, 6, and 12 months after surgery. Neurological and radiological evaluations were completed at each visit. Routine laboratory assessment of blood samples (red blood cell count, white blood cell count, and levels of hemoglobin, sodium, chloride, potassium, calcium, inorganic phosphate, carbon dioxide, magnesium, albumin, total protein, alkaline phosphatase [ALP], gamma-glutamyl transpeptidase [GGT], aspartate aminotransferase [AST], and alanine transaminase [ALT]) was performed preoperatively and again at 6 weeks and 3 months after surgery. Blood samples were also collected for immunological testing preoperatively and at 6 weeks and 3 months postoperatively and were evaluated for the potential formation of antibodies to the B2A peptide.
Statistical methods
Statistical testing was performed using 1-way and 2-way ANOVAs for numerical results and the chi-square test for categorical data. A p value less than 0.05 was considered significant. Recognizing the potential for Type II error due to small numbers in this Phase I clinical trial, we also report results with the use of summary statistics such as mean and standard deviation.
results
Most demographic variables were well balanced at taBle 2. Key inclusion and exclusion criteria for the study
Inclusion Criteria
Skeletally mature (18- to 70-year-old) male or a non-pregnant, nonlactating female Preoperative screening low back pain or leg pain of at least 6 cm using a 10-cm VAS Preoperative screening score of at least 20 points (40%) on the ODI Documented single-level degenerative disorder of the lumbar spine (DDD, spinal stenosis, up to Grade I spondylolisthesis at L-2 to S-1) Eligible to undergo a single-level TLIF (L-2 to S-1) Non-responsive to at least 6 months of non-operative treatment (e.g., bed rest, back school, epidural injections, physical therapy, etc.) prior to study enrollment Exclusion Criteria
History of previous surgery in the lumbar spine with or without attempted fusion Grade II or greater spondylolisthesis More than 0° of kyphosis at the operated disc space Evidence of scoliosis in the lumbar region of more than 10°C ollapsed disc space with bridging osteophytes Systemic infection or local infection at the site of surgery Acute fracture of the spine at the time of enrollment in the study Active history of systemic malignancy. History of any autoimmune disease, such as SLE, Addison's disease, Crohn's disease, or rheumatoid arthritis Receiving treatment (before or during surgery) with a drug (e.g., corticosteroids, methotrexate, etc.) that interferes with bone metabolism or are being treated with a bone growth stimulator Coverage under workers' compensation insurance Participation in clinical studies evaluating investigational devices, pharmaceuticals or biologics within 3 months of enrollment Use of tobacco products within 6 weeks preceding enrollment Known to require additional surgery to the lumbar spinal region within the next 6 months Have previously been treated with, or exposed to, therapeutic levels of BMPs Have an ORAI score >9 points and, if so, a DEXA scan T-score result of ≥2.5 standard deviations below the adult mean BMP = bone morphogenetic protein; DDD = degenerative disc disease; DEXA = dual-energy X-ray absorptiometry; ORAI = Osteoporosis Risk Assessment Instrument; SLE = systemic lupus erythematosus. baseline (Table 1) . ANOVA revealed a statistically significant difference in the preoperative body mass index (BMI) of the 3 groups. However, post-test analysis revealed a statistically significant difference in BMI only between the control and Prefix 150 groups. Preoperative ODI scores and baseline VAS scores for low-back and right leg pain showed no statistically significant difference between the 3 groups (Table 1) . However, ANOVA of the baseline VAS scores showed that the mean VAS scores for left leg and left hip pain in the Prefix 750 group were significantly higher than in the Prefix 150 group. The baseline VAS score for right hip pain in the Prefix 750 group was significantly higher than in the control group. There was no statistically significant difference between the baseline VAS scores in the control group and the Prefix 150 group.
The mean blood loss during surgery was higher in the control group (569 ml) than in either the Prefix 150 (364 ml) or Prefix 750 (314 ml) group, but this difference was not statistically significant. There was no significant difference in the length of hospital stay or the duration of surgery between the 3 groups, as shown in Table 3 .
At 6 months postsurgery (Fig. 4) , the Prefix 750 group had the highest fusion rate (71.4%), while the radiographic fusion rates in the Prefix 150 and control groups were 37.5% and 33.3%, respectively; the differences were not statistically significant, however, given the small group size (p = 0.27). By 12 months after surgery (Fig. 4) , all patients in the Prefix 750 group demonstrated fusion, resulting in a radiographic fusion rate of 100%, compared with a rate of 78% in the control group and only 50% in the Prefix 150 group (p = 0.08).
The ODI scores are shown in Table 4 and Fig. 5 . The Prefix 750 group had the highest mean preoperative ODI score at 64.6 (SD 13.3) compared with 60.9 (SD 16.3) for the control group and 49.8 (SD 9.1) for the Prefix 150 group (p > 0.05). Six weeks postoperatively, the mean ODI score dropped to 27.7 (SD 21.1) for the Prefix 750 group, to 32.2 (SD 21.8) for the Prefix 150 group, and to only 41 (SD 11.7) for the control group (p > 0.05). However, the difference in postoperative scores diminished by 3 months after surgery, and by 12 months postoperatively, the mean ODI score was 31.1 (SD 17.6) for the Prefix 750 group, 24.4 (SD 15.7) for the control group, and 29.7 (SD 20.7) for the Prefix 150 group (p > 0.05). There were statistically significant within-group differences in the ODI scores for the control group and the Prefix 750 group from the preoperative values to all postoperative stages. However, there was no statistically significant difference in ODI values of the Prefix 150 group at the different time points. At the 12-month follow-up evaluation, 100% of patients in the Prefix 750 group had an ODI score that was at least 15 points less than their preoperative score. Similar success (100% of patients) was seen in the control group, whereas only 62.5% of the patients in the Prefix 150 group showed this improvement of at least 15 points, with 2 patients (25%) in the Prefix 150 group showing an increase in ODI by 12 months after surgery.
VAS scores were recorded for all patients preoperatively and then at each postoperative follow-up visit separately for low-back, left hip, left leg, right hip, and right leg pain (Table 4 , Fig. 6 and 7) . Compared with preoperative status, the combined VAS scores showed statistically significant improvement at all postoperative stages for all 3 groups. However, 2-way ANOVA of VAS scores showed no statistically significant difference between the 3 groups at any postoperative time point.
There were no statistically significant differences between the 3 groups with respect to complication rates (Table 5 ). Figure 8 shows the CT scan of a patient in the Prefix 750 group who developed adjacent-level discitis. No patients developed antibodies to the B2A peptide.
discussion
The results of our study suggest that Prefix mixed with local autogenous bone graft is a viable alternative to iliac crest bone graft (ICBG) for achieving interbody fusion in patients undergoing the TLIF procedure. However, Prefix avoids the need for harvesting autograft from a separate site and hence avoids the complications and morbidities linked with ICBG harvesting. 5, 7, [12] [13] [14] 19, 20, 22, 23, 26, 28, 30, 31 Other substances used for lumbar interbody fusion have failed to show the optimal combination of efficacy and safety. Allograft has been associated with inferior fusion rates and higher graft resorption rates 14 and has the potential for disease transmission and immunogenicity, 16 whereas rhBMPs have been linked to a variety of complications. Our study demonstrated that Prefix can aid in successfully achieving lumbar interbody fusion in humans. We also demonstrated that the magnitude of this fusion is related to the concentration of Prefix used. All patients in the Prefix 750 group demonstrated fusion by 12 months compared with 77.8% in the control group and 50% in the Prefix 150 group. It seems that the Prefix 150 concentration is too low to be bioactive, and thus in this group the ceramic granules act more like uncoated ceramic granules, resulting in a fusion rate that is lower than in the control group. 26 However, these differences were not statistically significant.
In this study, VAS and ODI scores followed a similar trend. Mean VAS and ODI scores were improved in all patient groups at 12 months compared with preoperative values. It is worth noting that the ODI scores for the control group were elevated (mean 41.0), although not to a statistically significant extent, compared with both Prefix groups (mean 27.7 for Prefix 750, 32.29 for Prefix 150) at 6 weeks after surgery, presumably due to the early morbidity associated with ICBG harvest. Fortunately, this effect seemed to have improved by the 12-month time point, as has been previously reported in the literature. 23 Considering these early results in a small group of patients, one can surmise that Prefix 750, combined with local autogenous graft, provides an attractive alternative to ICBG, providing a safe, synthetic material that achieved fusion at least as well as ICBG autograft, while avoiding the morbidities associated with ICBG harvest. Nevertheless we acknowledge that a larger study will be necessary to fully define the safety profile of Prefix and wish to reiterate that even though we have highlighted the early differences between the 3 study groups, none of these differences were statistically significant given the small sample size.
One limitation of our study is the use of ICBG as the control group. A large number of surgeons routinely use 17 and without the drawback of increased donor site morbidity. In the future, it would be interesting to compare Prefix to local autograft for interbody fusion, rather than using ICBG as a control; such a study would more clearly define any additive effects of the Prefix itself.
Safety of a product is difficult to determine in a small study, but between 3 and 4 reversible adverse events were recorded in each group. There was not a preponderance of adverse events in any one group. Of importance is the fact that there was no increase in leg pain (radiculitis) in the Prefix groups compared with the ICBG group, which has been a concerning issue with rhBMP-2. Furthermore, Prefix showed no greater evidence of causing heterotopic bone, vertebral osteolysis, or periradicular bone formation than did ICBG. This may be related to the inability of B2A to generate bone in BMP-2-deficient environments and may avoid the documented perineural heterotopic bone formation observed with rhBMP-2. 2, 3, 10, 14, 24, 29 It is acknowledged that only a large study will be able to accurately define the frequency of this relatively rare event.
conclusions Prefix 750 mixed with local autogenous bone graft provided a safe and effective alternative to ICBG with no lasting complication. Prefix 750 showed a numerically superior fusion rate and ODI improvement rate compared with ICBG at 12 months, although statistical significance was not reached. Prefix avoided the initial morbidity associated with ICBG while showing statistically comparable improvements in ODI and VAS scores compared with the control (ICBG) group. Prefix appears to be a promising bone graft agent and should be studied further in a larger clinical trial with a longer-term endpoint. 
